hypothyroidism: Abnormally low levels of thyroid hormone.
Hypothyroidism due to medicaments and other exogenous substances
DOID EFO Endpoint Browser PheWeb
E4_HYTHYSUBS
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
376 |
4. Check minimum number of eventsNone |
376 |
5. Include endpointsNone |
376 |
6. Filter based on genotype QC (FinnGen only) |
376 |
Control definitions (FinnGen only)
- Control exclude
- E4_THYROID
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- E03
- Name in latin
- Hypothyreosis ex medicamentis sive aliis substantiis externis
Similar endpoints
↥List of similar endpoints to
Hypothyroidism due to medicaments and other exogenous substances
based on the number of shared cases.
Similar with more cases:
- Hypothyroidism (congenital or acquired)
- Hypothyreosis and Thyroxine purchase for inclusion criteria
- Disorders of the thyroid gland
- Used for control exclusion in common control thyroid runs
- Endocrine, nutritional and metabolic diseases
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2311 | 1701 | 600 |
| Only index persons | 2080 | 1546 | 534 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.04 | 0.05 | 0.02 |
| Only index persons | 0.05 | 0.06 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 61.87 | 61.63 | 62.70 |
| Only index persons | 60.73 | 60.33 | 61.91 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 376 | 271 | 105 |
| Unadjusted period prevalence (%) | 0.08 | 0.09 | 0.05 |
| Median age at first event (years) | 58.55 | 56.85 | 62.93 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 332
- Matched controls
- 3320
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H03AA01
ATC
levothyroxine sodium; systemic
1347.5
323.0
314
42
E03.2
ICD-10 Finland
Hypothyroidism due to medicaments and other exogenous substances
+∞
323.0
317
*
H03BB01
ATC
carbimazole; oral
1221.4
158.2
142
*
E03.9
ICD-10 Finland
Hypothyroidism, unspecified
504.4
135.2
126
*
104
Kela drug reimbursment
Thyroid insufficiency
559.9
118.6
111
*
E05.0
ICD-10 Finland
Thyrotoxicosis with diffuse goitre
+∞
111.9
101
*
E05.9
ICD-10 Finland
Thyrotoxicosis, unspecified
+∞
92.0
84
*
E89.00
ICD-10 Finland
Postirradiation hypothyroidism
+∞
52.5
49
*
E03
ICD-10 Finland
Other hypothyroidism
119.7
39.7
42
*
E03.89
ICD-10 Finland
Other specified hypothyroidism
142.4
36.5
38
*
T86
ICPC
Hypothyroidism/myxoedema
65.6
26.4
30
5
E05.2
ICD-10 Finland
Thyrotoxicosis with toxic multinodular goitre
+∞
23.2
22
*
XX7CT
NOMESCO Finland
Radioiodine therapy of thydoid tissue
+∞
21.1
20
*
N05AN01
ATC
lithium; oral
15.6
20.9
34
24
C07AA05
ATC
propranolol; systemic
3.7
20.7
107
376
E04.2
ICD-10 Finland
Nontoxic multinodular goitre
58.6
19.2
22
*
E05
ICD-10 Finland
Thyrotoxicosis [hyperthyroidism]
+∞
18.9
18
*
E03.80
ICD-10 Finland
Hypothyroidism caused by autoimmune thyroiditis
+∞
18.9
18
*
C01BD01
ATC
amiodarone; systemic
12.5
17.9
32
28
2443X
ICD-9 Finland
Acquired hypothyroidism, Other iatrogenic hypothyroidism
+∞
16.8
16
*
E89.01
ICD-10 Finland
Postsurgical hypothyroidism
+∞
15.7
15
*
BAA60
NOMESCO Finland
Total thyroidectomy
59.5
14.9
17
*
1502
Kela drug reimbursment
Cabozantinib
+∞
12.6
12
*
3012
Kela drug reimbursment
Cabozantinib
+∞
12.6
12
*
112
Kela drug reimbursment
Severe psychotic and other severe mental disorders
4.3
12.2
46
119
WD515
NOMESCO Finland
Demanding therapy of malignancy with enzyme inhibitors and similar treatments
67.4
11.7
13
*
F31.9
ICD-10 Finland
Bipolar affective disorder, unspecified
10.6
11.7
22
22
F31.30
ICD-10 Finland
Bipolar disorder Depressive episode without somatic syndrome
14.5
11.1
18
13
O99.2
ICD-10 Finland
Endocrine, nutritional and metabolic diseases complicating pregnancy, childbirth and the puerperium
44.9
11.0
13
*
C07AB07
ATC
bisoprolol; oral
2.2
10.9
173
1095
E05.80
ICD-10 Finland
Subacute thyrotoxicosis
113.4
10.5
11
*
H06.2*E05.9
ICD-10 Finland
Dysthyroid exophthalmos
+∞
10.5
10
*
E05.1
ICD-10 Finland
Thyrotoxicosis with toxic single thyroid nodule
+∞
10.5
10
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.2
10.3
156
959
130
Kela drug reimbursment
Malignant tumour
3.7
10.0
44
131
F31.0
ICD-10 Finland
Bipolar affective disorder, current episode hypomanic
20.8
9.9
14
7
TPH04
NOMESCO Finland
Cathetrisation of vein
2.5
9.6
86
410
E05.89
ICD-10 Finland
Other thyrotoxicosis
+∞
9.4
9
*
E89.09
ICD-10 Finland
Postprocedural hypothyroidism, other or several procedures
+∞
9.4
9
*
EP1AE
NOMESCO Finland
Neck ultrasound examination
4.9
9.4
30
66
N05AX12
ATC
aripiprazole; systemic
6.6
8.9
22
35
F31.1
ICD-10 Finland
Bipolar affective disorder, current episode manic without psychotic symptoms
51.3
8.7
10
*
F31.6
ICD-10 Finland
Bipolar affective disorder, current episode mixed
13.2
8.4
14
11
F31.7
ICD-10 Finland
Bipolar affective disorder, currently in remission
9.8
8.4
16
17
L01XE26
ATC
[U] cabozantinib; oral
+∞
8.4
8
*
ZX120
NOMESCO Finland
Intravenous
3.1
8.1
45
159
N05AA02
ATC
levomepromazine; systemic
5.4
8.0
23
45
N05AF03
ATC
chlorprothixene; systemic
6.4
8.0
20
33
WD325
NOMESCO Finland
Demanding therapy of methastized malignancy with biomodifiers
13.5
7.9
13
10
N05AH03
ATC
olanzapine; systemic
4.0
7.9
31
84
C03CA01
ATC
furosemide; systemic
2.1
7.7
97
539
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
2.5
7.6
62
278
N02BE01
ATC
paracetamol; systemic, rectal
2.4
7.6
291
2476
XF400
NOMESCO Finland
ECG with 12 standard connections
2.5
7.5
61
271
N03AG01
ATC
valproic acid; systemic, rectal
3.7
7.4
31
89
N05AH04
ATC
quetiapine; oral
2.5
7.3
61
277
L01EX07
ATC
cabozantinib; oral
+∞
7.3
7
*
E04.9
ICD-10 Finland
Nontoxic goitre, unspecified
16.2
7.3
11
7
C03DA01
ATC
spironolactone; oral
3.0
7.3
42
154
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.5
7.2
57
252
F31.8
ICD-10 Finland
Other bipolar affective disorders
10.3
7.1
13
13
C64.88
ICD-10 Finland
Other malignant neoplasm of kidney, except renal pelvis
7.2
7.1
16
23
H02AB06
ATC
prednisolone; systemic
1.9
7.0
156
1065
WX892
NOMESCO Finland
Monitored bed care
3.6
6.9
30
89
A03FA01
ATC
metoclopramide; systemic, rectal
2.1
6.8
84
456
N05BA04
ATC
oxazepam; oral
2.1
6.8
91
513
B01AB05
ATC
enoxaparin; parenteral
1.9
6.8
114
703
N05CF01
ATC
zopiclone; oral
1.9
6.7
117
730
BA3AT
NOMESCO Finland
Cytology of thyroid with ultrasound quidance
10.3
6.6
12
12
B01AA03
ATC
warfarin; systemic
2.3
6.6
67
335
H02AB09
ATC
hydrocortisone; systemic
7.6
6.5
14
19
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
4.5
6.4
21
49
N05AX08
ATC
risperidone; systemic
3.2
6.3
31
102
BAA40
NOMESCO Finland
Unilateral lobectomy of thyroid gland
18.4
6.3
9
5
H06.2
ICD-10 Finland
Dysthyroid exophthalmos
+∞
6.3
6
*
N03AX09
ATC
lamotrigine; oral
4.1
6.1
22
56
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
153
102
24.61
185.20
6.1
1.5
4.3
4.4
pmol/l
0.60
140
90
97
42
30.78
139.07
2.8
1.2
6.4
1.0
iu/l
—
49
8
359
2308
13.29
38.57
13.7
2.6
15.7
14.4
pmol/l
15.94
344
2084
74
170
5.17
31.31
1.3
1.2
298.1
90.9
iu/ml
0.72
37
60
88
258
4.15
27.17
5.7
1.9
376.6
372.7
nmol/l
0.06
83
232
255
1494
3.20
24.86
10.3
5.9
1.2
1.2
mmol/l
0.04
210
1262
237
1353
3.03
23.81
8.9
5.1
1.2
1.2
mmol/l
0.13
221
1224
115
476
3.04
20.23
5.2
2.6
0.8
0.8
mmol/l
0.06
110
453
359
2847
6.77
17.43
15.4
3.5
2.5
1.9
mu/l
2.21
345
2583
210
1273
2.47
16.43
2.8
2.3
75.5
77.8
nmol/l
0.61
193
1133
18
19
9.90
15.33
3.4
1.8
17.8
24.5
nmol/l
1.19
18
19
66
236
3.18
14.59
9.2
5.9
10.0
9.1
mmol/l
0.49
61
225
64
228
3.18
14.22
3.9
3.2
78.5
74.1
ng/l
0.17
57
204
255
1779
2.35
13.29
18.0
8.7
3.9
4.1
e9/l
0.78
224
1552
174
1045
2.24
12.98
5.5
3.2
2.3
2.4
mmol/l
0.42
155
921
200
1293
2.17
12.16
6.4
4.1
34.6
35.6
g/l
1.49
186
1208
247
1762
2.17
11.32
7.3
4.2
6.9
6.6
mmol/l
1.16
236
1646
160
990
2.07
10.49
4.7
3.0
26.7
30.8
u/l
1.92
150
947
305
2417
2.39
10.11
13.4
7.0
77.1
77.8
u/l
0.14
292
2267
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
26
63
4.36
10.06
3.1
2.3
0.3
0.3
u/ml
0.52
13
33
63
270
2.60
9.83
5.1
3.4
1.6
2.0
mmol/l
0.59
51
216
85
422
2.31
9.62
2.8
2.0
2.4
2.4
g/l
0.10
80
385
268
2035
2.10
9.61
6.4
4.4
545.2
2115.5
e6/l
—
6
33
81
401
2.30
9.20
3.1
2.1
19.7
23.0
%
1.14
69
349
225
1637
1.93
8.72
10.4
5.7
9.9
10.9
umol/l
1.08
216
1559
151
963
1.95
8.71
4.9
2.3
58.9
55.4
u/l
0.72
143
899
140
871
1.97
8.68
3.6
3.0
1948.2
1124.1
ng/l
1.59
128
734
67
314
2.38
8.60
6.8
6.9
5.0
5.1
kpa
0.55
62
300
67
314
2.38
8.60
6.8
6.9
12.2
12.1
kpa
0.01
62
301
19
41
4.83
8.44
5.1
4.2
365.4
364.2
umol/l
0.01
14
36
67
317
2.36
8.41
6.8
6.9
0.3
1.5
mmol/l
1.76
51
252
87
467
2.12
8.02
3.0
2.0
11.9
13.2
umol/l
1.02
82
423
69
339
2.27
7.91
2.0
1.8
—
—
—
0
0
68
333
2.27
7.86
1.9
1.8
—
—
—
0
0
134
851
1.89
7.62
5.1
2.8
0.3
0.5
e6/l
0.96
98
624
163
1102
1.85
7.61
5.4
2.9
—
—
—
0
0
209
1536
1.81
7.32
5.0
3.7
0.0
0.0
estimate
0.00
52
296
190
1361
1.80
7.22
3.5
2.6
133.9
111.8
ug/l
0.68
172
1247
98
571
1.97
7.15
4.3
2.7
2.5
2.5
mmol/l
1.05
82
498
86
486
2.00
6.82
2.0
1.8
—
—
—
0
0
84
472
2.00
6.76
5.1
2.8
3.4
2.4
e6/l
0.38
48
232
171
1204
1.77
6.76
2.3
2.0
92.2
96.2
pmol/l
0.45
89
605
95
564
1.92
6.50
5.4
3.4
156.5
268.7
ng/l
0.39
74
425
209
1570
1.75
6.49
5.1
3.7
0.0
0.0
estimate
0.50
52
285
206
1551
1.73
6.26
6.7
5.1
0.0
0.0
estimate
0.50
54
301
116
743
1.81
6.21
3.0
2.1
2.8
3.2
mg/l
0.85
100
637
115
736
1.81
6.17
1.6
1.5
20.8
21.9
nmol/l
0.40
103
622
162
1147
1.72
6.11
5.3
3.7
31.2
63.8
ng/l
0.53
123
806
283
2342
1.84
6.08
5.1
3.9
16.8
11.9
mm/h
3.92
263
2155
308
2623
1.96
5.99
33.1
15.9
13.9
13.7
%
1.64
303
2580
68
371
2.02
5.90
25.4
21.9
1.2
1.2
inr
—
8
43
84
494
1.90
5.86
4.7
2.6
1.2
1.2
e6/l
0.03
48
255
55
281
2.12
5.68
2.5
2.2
28.4
29.3
u/l
0.15
47
233
16
42
3.93
5.59
1.2
1.6
—
—
—
0
0
348
3129
2.51
5.46
25.2
13.1
21.2
22.8
mg/l
0.51
307
2414
58
308
2.04
5.40
4.0
3.3
—
—
—
0
0
42
196
2.29
5.40
1.8
1.7
—
—
—
0
0
130
898
1.68
5.19
5.7
3.9
14.7
8.9
mg/mmol
0.63
87
548
352
3202
2.56
5.00
30.0
15.1
4.0
4.0
mmol/l
1.38
347
3107
14
41
3.51
4.22
1.4
1.2
113.0
118.2
u/ml
—
5
9
184
1443
1.54
4.09
4.4
3.9
—
—
—
0
0
37
186
2.10
3.99
1.7
1.7
—
—
—
0
0
35
175
2.10
3.83
1.8
1.3
—
—
—
0
0
102
709
1.60
3.81
1.8
1.7
1.9
1.2
mg/l
0.82
73
566
18
66
2.81
3.81
3.7
2.3
18.7
15.9
%
—
10
36
15
51
3.02
3.61
1.3
1.8
—
—
—
0
0
127
939
1.53
3.60
2.6
2.0
190.4
188.2
u/l
0.02
120
891
19
75
2.61
3.52
1.4
1.7
—
—
—
0
0
102
724
1.56
3.45
2.5
2.2
—
—
—
0
0
20
82
2.52
3.44
6.8
4.0
1.7
1.6
mg/l
0.19
20
74
19
76
2.58
3.43
1.3
1.7
—
—
—
0
0
355
3319
2.25
3.37
17.8
10.0
24.5
24.7
u/l
0.14
350
3211
13
43
3.10
3.28
1.3
1.2
—
—
—
0
0
116
856
1.51
3.27
1.8
1.6
1.5
1.3
mmol/l
0.89
98
720
80
543
1.60
3.26
2.1
1.7
1103.8
1258.2
nmol/l
0.97
66
399
8
15
5.42
3.20
1.4
1.8
72.0
55.1
ug/l
—
8
15
104
761
1.51
3.03
2.5
2.5
339.6
7971.9
umol/l
3.96
83
671
53
330
1.71
3.01
3.8
2.6
5.3
6.7
umol/l
0.66
45
288
12
40
3.07
3.00
1.4
1.4
0.6
0.6
nmol/l
0.09
12
35
12
40
3.07
3.00
1.8
1.3
—
—
—
0
0
151
1198
1.44
2.88
5.3
3.9
—
—
—
0
0
6
9
6.75
2.88
1.3
1.4
407.5
106.3
iu/ml
—
6
9
11
36
3.12
2.83
1.4
1.6
90.6
90.7
%
0.01
11
36
9
23
3.98
2.79
1.1
1.9
—
—
—
0
0
351
3299
1.96
2.77
31.1
15.6
82.6
74.0
umol/l
3.97
351
3299
14
54
2.65
2.73
3.0
2.7
3.8
4.7
e9/l
1.21
14
54
18
80
2.31
2.65
2.7
2.3
—
—
—
0
0
14
56
2.56
2.56
3.1
3.2
58.2
58.4
%
0.02
14
56
19
88
2.22
2.55
3.1
4.0
—
3.1
—
0
8
10
33
3.09
2.54
1.1
1.7
—
—
—
0
0
75
531
1.52
2.52
1.3
1.3
11.4
7.0
u/ml
0.24
25
196
7
16
4.44
2.48
1.1
1.9
—
—
—
0
0
17
76
2.30
2.48
1.9
1.4
—
—
—
0
0
7
17
4.17
2.37
1.1
1.8
—
—
—
0
0
78
566
1.48
2.33
1.3
1.3
17.7
29.3
iu/ml
1.44
20
189
10
35
2.91
2.32
1.3
1.7
—
—
—
0
0
11
41
2.73
2.29
1.1
1.6
—
—
—
0
0
108
841
1.40
2.20
6.4
3.8
0.0
0.0
estimate
0.50
54
293
9
30
3.05
2.16
1.2
1.9
—
—
—
0
0
7
19
3.73
2.16
1.1
1.8
—
—
—
0
0
85
642
1.42
2.05
1.8
1.7
455.5
13800053.3
pmol/l
0.50
71
529
6
15
4.05
2.04
1.2
1.3
—
—
—
0
0
15
70
2.19
2.01
1.4
1.3
—
—
—
0
0
13
59
2.25
1.86
1.2
1.5
—
—
—
0
0
324
3040
1.48
1.85
5.7
4.5
6.1
5.9
mmol/l
1.10
299
2776
315
2944
1.43
1.80
25.2
12.2
76.5
80.5
ml/min/173m2
2.50
284
2397
14
269
0.50
1.79
1.7
1.8
—
—
—
0
0
25
147
1.75
1.79
2.3
2.1
11.5
12.7
nmol/l
0.37
20
138
10
42
2.42
1.69
1.2
1.6
—
—
—
0
0
11
49
2.28
1.65
1.2
1.6
—
—
—
0
0
87
684
1.35
1.64
1.3
1.2
2.1
2.4
u/ml
0.05
22
181
10
43
2.36
1.61
1.5
1.1
2.2
1.5
u/ml
—
5
11
17
92
1.89
1.58
1.4
1.6
0.0
0.2
iu/ml
—
7
20
17
92
1.89
1.58
1.2
1.4
1.3
1.2
g/l
0.82
17
87
308
2885
1.37
1.58
6.9
5.6
42.0
39.7
mmol/mol
2.76
292
2698
28
177
1.63
1.57
5.4
4.4
2.4
2.0
mmol/l
0.24
19
134
14
71
2.01
1.56
1.4
1.2
—
—
—
0
0
37
251
1.53
1.55
5.3
2.6
55.8
64.9
ml/min/173m2
1.19
21
100
18
101
1.82
1.51
2.1
1.6
—
—
—
0
0
10
45
2.26
1.47
1.1
1.2
14.1
13.7
u/l
—
10
39
331
3148
1.43
1.45
5.7
4.9
2.7
2.8
mmol/l
0.97
307
2902
5
16
3.15
1.44
1.6
1.5
—
—
—
0
0
226
2043
1.27
1.44
3.5
3.0
52.3
44.1
u/l
0.74
213
1915
15
82
1.86
1.37
3.4
1.9
119.0
690.7
u/l
—
7
28
5
17
2.97
1.36
2.4
1.9
—
—
—
0
0
14
76
1.87
1.31
1.1
1.3
—
—
—
0
0
5
18
2.80
1.29
2.0
3.3
—
—
—
0
0
19
117
1.66
1.20
4.6
1.7
—
—
—
0
0
8
38
2.13
1.19
2.1
1.9
15.2
17.9
ug/l
—
8
38
299
2827
1.28
1.15
27.8
14.0
38.6
39.3
%
0.67
209
2046
19
119
1.63
1.14
1.8
1.6
—
—
—
0
0
8
40
2.02
1.12
3.5
1.3
—
—
—
0
0
11
59
1.89
1.08
1.0
1.2
—
—
—
0
0
11
59
1.89
1.08
1.0
1.2
—
—
—
0
0
13
75
1.76
1.04
1.5
1.3
—
—
—
0
0
5
22
2.29
1.03
1.2
1.2
—
—
—
0
0
323
3095
1.31
1.03
5.2
4.3
4.6
4.7
mmol/l
2.04
303
2879
5
23
2.19
0.98
1.0
1.0
—
—
u/ml
—
0
0
312
2983
1.27
0.97
4.5
3.8
1.4
1.2
mmol/l
2.34
291
2737
0
31
0.00
0.97
0.0
1.1
—
—
—
0
0
44
341
1.33
0.94
2.6
1.8
1.5
1.5
%
0.11
35
299
18
120
1.53
0.87
1.3
1.5
—
—
—
0
0
6
111
0.53
0.84
1.5
1.5
—
—
—
0
0
208
1931
1.17
0.80
3.2
3.0
—
—
—
0
0
0
26
0.00
0.78
0.0
1.2
—
—
—
0
0
319
3079
1.24
0.76
5.1
4.3
1.4
1.5
mmol/l
3.07
296
2845
5
24
2.10
0.75
2.4
1.2
1.4
2.9
ug/l
—
5
19
5
24
2.10
0.75
1.0
1.3
—
—
—
0
0
7
38
1.86
0.74
3.9
4.5
—
—
—
0
0
7
39
1.81
0.73
1.7
1.6
—
—
—
0
0
7
40
1.76
0.71
1.3
1.1
—
—
—
0
0
5
26
1.94
0.71
1.8
1.8
—
—
—
0
0
5
26
1.94
0.71
1.8
1.8
—
—
—
0
0
5
26
1.94
0.71
1.8
1.8
—
—
—
0
0
9
58
1.57
0.70
1.1
1.7
—
—
—
0
0
7
41
1.72
0.70
1.4
1.5
—
—
—
0
0
5
28
1.80
0.66
1.0
1.4
—
—
—
0
0
20
147
1.38
0.63
2.0
1.8
—
—
—
0
0
0
21
0.00
0.60
0.0
1.0
—
—
—
0
0
63
545
1.19
0.57
1.5
1.4
—
—
—
0
0
14
101
1.40
0.50
1.2
1.1
—
—
—
0
0
14
101
1.40
0.50
1.2
1.1
—
—
—
0
0
7
45
1.57
0.49
1.9
1.3
—
—
—
0
0
7
45
1.57
0.49
1.9
1.3
—
—
—
0
0
7
45
1.57
0.49
3.9
3.6
27.3
84.0
u/ml
—
7
45
7
45
1.57
0.49
1.9
1.3
—
—
—
0
0
7
45
1.57
0.49
1.9
1.3
—
—
—
0
0
7
46
1.53
0.48
1.9
1.3
—
—
—
0
0
7
46
1.53
0.48
1.9
1.3
—
—
—
0
0
5
34
1.48
0.40
1.4
1.4
—
—
—
0
0
0
19
0.00
0.39
0.0
1.3
—
—
—
0
0
5
36
1.39
0.38
1.0
1.2
—
—
—
0
0
9
67
1.35
0.38
1.1
1.3
—
—
—
0
0
39
339
1.17
0.36
4.0
4.1
2.9
10.0
ug/l
2.89
32
280
6
41
1.47
0.36
1.2
1.1
6.9
7.1
mmol/l
—
6
26
6
42
1.44
0.35
1.0
1.0
—
—
—
0
0
10
75
1.34
0.30
1.6
1.2
4.3
3.8
mmol/l
—
10
69
33
375
0.87
0.29
3.9
4.3
32.3
32.9
%
0.09
22
247
9
73
1.24
0.25
1.6
1.4
—
—
—
0
0
74
691
1.09
0.24
3.6
5.1
1.7
3.0
ug/l
1.59
62
615
5
42
1.19
0.21
1.0
1.2
—
—
—
0
0
5
42
1.19
0.21
1.4
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
14
0.00
0.20
0.0
4.9
—
216.4
—
0
14
6
49
1.23
0.20
1.2
1.3
—
—
—
0
0
6
51
1.18
0.19
1.2
1.7
—
—
—
0
0
10
81
1.24
0.19
1.1
1.4
—
—
—
0
0
8
70
1.15
0.16
1.4
1.4
—
—
—
0
0
7
86
0.81
0.14
2.7
3.3
23.6
27.0
u/ml
—
7
86
17
188
0.90
0.11
1.3
1.3
—
27.7
—
0
10
5
46
1.09
0.09
1.2
1.1
—
—
—
0
0
7
68
1.03
0.08
1.6
1.6
—
—
—
0
0
9
103
0.87
0.06
1.4
1.6
—
—
—
0
0
27
283
0.95
0.05
2.5
1.9
—
—
—
0
0
11
100
1.10
0.05
1.2
1.9
—
—
—
0
0
39
403
0.96
0.04
2.3
3.2
0.6
0.8
ug/l
0.97
23
264
15
160
0.93
0.04
1.1
1.0
—
—
—
0
0
51
520
0.98
0.02
1.6
1.5
—
—
—
0
0
37
363
1.02
0.01
10.7
7.2
—
—
—
0
0
56
553
1.01
0.01
3.0
4.5
24.3
20.9
%
0.72
16
277
16
166
0.96
0.00
1.3
1.3
—
—
—
0
0
25
256
0.97
0.00
2.3
1.8
—
—
—
0
0
12
117
1.03
0.00
1.5
2.0
—
—
—
0
0
11
115
0.96
0.00
1.5
1.8
—
—
—
0
0
10
96
1.04
0.00
1.5
1.5
—
—
—
0
0
(3002348) Coagulation factor XII activity actual/normal in Platelet poor plasma by Coagulation assay
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
8
85
0.94
0.00
1.8
1.7
—
—
—
0
0
8
82
0.98
0.00
1.1
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
113.0
—
0
9
0
5
0.00
0.00
0.0
5.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
8
89
0.90
0.00
1.0
1.1
—
2.4
—
0
13
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint E4_HYTHYSUBS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_HYTHYSUBS | 1.474 [1.22, 1.77] | < 0.001 |
| Birth year | 0.992 [0.98, 1.0] | 0.062 |
During the follow-up period (1.1.1998 — 31.12.2019), 266 out of 1295 females with E4_HYTHYSUBS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_HYTHYSUBS | 1.706 [1.2, 2.43] | 0.003 |
| Birth year | 0.991 [0.98, 1.0] | 0.059 |
During the follow-up period (1.1.1998 — 31.12.2019), 125 out of 448 males with E4_HYTHYSUBS died.
Mortality risk
Mortality risk for people of age
years, who have E4_HYTHYSUBS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.126% | 0.325% |
| 5 | 0.678% | 1.992% |
| 10 | 1.908% | 5.386% |
| 15 | 3.619% | 10.489% |
| 20 | 6.044% | 17.534% |
Relationships between endpoints
↥Index endpoint: E4_HYTHYSUBS – Hypothyroidism due to medicaments and other exogenous substances
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data